halobetasol-tazarotene
Selected indexed studies
- Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. (Ann Pharmacother, 2020) [PMID:32126800]
- Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. (J Drugs Dermatol, 2023) [PMID:36745378]
- A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. (J Drugs Dermatol, 2017) [PMID:28301614]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials. (2020) pubmed
- Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion. (2023) pubmed
- A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis. (2017) pubmed
- Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. (2021) pubmed